301 related articles for article (PubMed ID: 27126005)
1. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening.
Chatzistamatiou K; Moysiadis T; Moschaki V; Panteleris N; Agorastos T
Gynecol Oncol; 2016 Jul; 142(1):120-127. PubMed ID: 27126005
[TBL] [Abstract][Full Text] [Related]
2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
[TBL] [Abstract][Full Text] [Related]
4. Primary HPV testing verification: A retrospective ad-hoc analysis of screening algorithms on women doubly tested for cytology and HPV.
Tracht J; Wrenn A; Eltoum IE
Diagn Cytopathol; 2017 Jul; 45(7):580-586. PubMed ID: 28436211
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
[TBL] [Abstract][Full Text] [Related]
6. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
[TBL] [Abstract][Full Text] [Related]
7. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
[TBL] [Abstract][Full Text] [Related]
10. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
[TBL] [Abstract][Full Text] [Related]
11. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
12. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
13. [Performance of combined liquid based cytology and HPV nucleic acid test for detecting cervical precancer among women attending screening].
Jiang MY; Feng RM; Wang L; Li TY; Zhang AA; Cui JF; Pan QJ; Zhang X; Liu ML; Gao F; Chen W; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):750-756. PubMed ID: 30392339
[No Abstract] [Full Text] [Related]
14. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.
Hernández-López R; Lorincz AT; Torres-Ibarra L; Reuter C; Scibior-Bentkowska D; Warman R; Nedjai B; Mendiola-Pastrana I; León-Maldonado L; Rivera-Paredez B; Ramírez-Palacios P; Lazcano-Ponce E; Cuzick J; Salmerón J;
Clin Epigenetics; 2019 Oct; 11(1):140. PubMed ID: 31606044
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
16. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
17. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC
Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study.
Cox JT; Castle PE; Behrens CM; Sharma A; Wright TC; Cuzick J;
Am J Obstet Gynecol; 2013 Mar; 208(3):184.e1-184.e11. PubMed ID: 23174289
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
